Lyell Immunopharma (NASDAQ:LYEL) Announces Earnings Results, Beats Expectations By $0.37 EPS

Key Points

• Lyell Immunopharma reported a quarterly loss of $1.69 per share, beating analysts’ estimate of a $2.06 loss. Revenue was effectively zero, consistent with its development-stage status.
• Updated ronde-cel trial results showed overall response rates of 91% in the 3L+ trial and 95% in a second-line cohort; severe cytokine release syndrome was not observed. Lyell plans to present the data at ASH 2026.
• The company agreed to an approximately $80 million private placement to advance ronde-cel toward a planned BLA submission; issuing shares could dilute existing shareholders.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($1.69) EPS for the quarter, beating the consensus estimate of ($2.06) by $0.37, reports. The firm had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.01 million. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%.

Lyell Immunopharma Stock Performance

Shares of Lyell Immunopharma stock traded up $4.63 during trading hours on Wednesday, hitting $15.40. The company's stock had a trading volume of 1,100,241 shares, compared to its average volume of 137,513. The business has a 50 day moving average price of $10.85 and a two-hundred day moving average price of $16.77. Lyell Immunopharma has a 12-month low of $7.20 and a 12-month high of $45.00. The company has a market cap of $377.28 million, a PE ratio of -1.20 and a beta of -0.04.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on LYEL shares. Royal Bank Of Canada set a $34.00 price objective on Lyell Immunopharma in a research note on Friday, August 14th. Citigroup reissued a "market outperform" rating on shares of Lyell Immunopharma in a report on Friday, August 14th. Stifel Nicolaus started coverage on shares of Lyell Immunopharma in a research note on Thursday, August 6th. They set a "buy" rating and a $36.00 target price on the stock. HC Wainwright restated a "buy" rating on shares of Lyell Immunopharma in a research note on Friday, September 11th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $44.00 price target on shares of Lyell Immunopharma in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $40.86.

Lyell Immunopharma News Roundup

Here are the key news stories impacting Lyell Immunopharma this week:

• Positive Sentiment: Promising ronde-cel results: Updated data showed overall response rates of 91% in 44 patients treated in the 3L+ PiNACLE pivotal trial and 95% in 37 patients in a Phase 1/2 second-line cohort. Complete response rates were 77% and 76%, respectively; median progression-free survival had not been reached. Severe cytokine release syndrome was not observed, and severe neurotoxicity occurred in fewer than 10% of patients. The data will be presented at ASH 2026. Lyell ronde-cel data
• Positive Sentiment: Funding for development: Lyell agreed to a private placement expected to raise approximately $80 million, with proceeds intended to advance ronde-cel toward a planned Biologics License Application (BLA) submission. Lyell private placement announcement
• Neutral Sentiment: Quarterly results: The company reported a loss of $1.69 per share, narrower than analysts’ expected $2.06 loss. Revenue was effectively zero, underscoring that Lyell remains a development-stage company. Third-quarter 2026 results
• Negative Sentiment: The private placement involves issuing common shares, which could dilute existing shareholders.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell's research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.